Therefore, the novel therapeutic strategy of the combination with IQM, a TLR‐7 agonist, and nivolumab, an anti‐PD‐1 mAb, efficiently rotates the cancer immune cycle by affecting the second and seventh steps of the cancer immunity cycle, respectively. The gene discussed is TLR7; the disease is cancer.